Latanoprost formulation - ISTA Pharmaceuticals/Senju

Drug Profile

Latanoprost formulation - ISTA Pharmaceuticals/Senju

Latest Information Update: 07 Jun 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senju Pharmaceutical
  • Developer ISTA Pharmaceuticals
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 10 Dec 2015 Biomarkers information updated
  • 06 Jun 2012 ISTA Pharmaceuticals has been acquired by Bausch & Lomb
  • 29 Oct 2007 Phase-I clinical trials in Glaucoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top